[Music] the drug semaglitide is formulated to help people with type 2 diabetes control their blood sugar sold as ozempic for diabetes some magnetite is also approved as a weight loss drug under the brand name wegovi both medications are self-administered once a week with an auto-injector ozempic and wegovi are glucagon-like peptide 1 or glp-1 agonists this means that they stimulate the production of encryptin a naturally occurring hormone that helps people feel full longer by slowing the rate the stomach empties ingridants also impact the hypothalamus a part of the brain that controls hunger signals reducing hunger and cravings a clinical trial conducted by the drug maker Novo Nordisk found that over the course of a 68-week study those who took weigovi lost 14.9 percent of their body weight those who receive the placebo control lost just 2.4 percent of their weight because of how some magnetite affects the stomach gastrointestinal side effects such as nausea and vomiting are possible and once a patient discontinues some magnetite use weight that has been lost can return wigovi is the only weekly glp-1 treatment approved for weight loss but competition is coming Eli Lilly has a drug which is expected to win approval this year and Amgen Pfizer and others are developing rival drugs that promise less frequent dosing more substantial weight loss or fewer side effects [Music]